Business Context and Reporting Period
AtriCure, Inc. is a medical device company specializing in cardiac surgical ablation systems (Isolator system) and left atrial appendage exclusion devices (AtriClip system) for the treatment of atrial fibrillation (AF). The company operates primarily in the United States and internationally through distributors and a European subsidiary. This summary covers the fiscal year ended December 31, 2010.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Revenue | $59.0 million | $54.5 million |
| Gross Profit | $45.4 million | $41.8 million |
| Gross Margin | 76.9% | 76.6% |
| Net Loss | $(3.8) million | $(16.5) million |
| Operating Expenses | $48.6 million | $57.3 million |
| Cash & Equivalents | $4.2 million | $8.9 million |
| Short-term Investments | $8.3 million | $6.8 million |
| Total Debt (Current + Long-term) | $2.9 million | $4.9 million |
| Working Capital | $17.6 million | $19.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 8.2% to $59.0 million, driven by $2.5 million in sales of new disposable cryoablation devices and $2.4 million from the AtriClip system (launched in the U.S. in Q2 2010).
- Profitability Improvement: Net loss narrowed significantly from $16.5 million in 2009 to $3.8 million in 2010. This improvement was primarily due to the absence of a $6.8 million goodwill impairment charge and a $4.0 million DOJ settlement reserve recorded in 2009.
- Operating Expenses: Total operating expenses decreased by $8.7 million year-over-year, largely due to the resolution of the DOJ investigation and related class action lawsuits, which reduced legal expenses.
- International Sales: International revenue grew 10.3% to $11.5 million, representing 19% of total revenue.
Guidance, Outlook, Risks, and Unusual Items
- Regulatory Status: The company has not received FDA approval to market its products specifically for the treatment of AF. It is pursuing a Premarket Approval (PMA) for the Isolator system based on the ABLATE clinical trial. In March 2011, the FDA issued a major deficiency letter regarding this PMA.
- Legal Proceedings: The company settled a Department of Justice (DOJ) investigation regarding off-label marketing and billing practices in February 2010 for approximately $4.4 million (including interest). It also settled two securities class action lawsuits in 2010 for a total of $4.75 million, which were funded by insurance.
- Compliance: The company entered into a five-year Corporate Integrity Agreement with the Office of Inspector General (OIG) as part of the DOJ settlement. In February 2011, the FDA issued a Form 483 citing deficiencies at the company's manufacturing facility; the company has responded with corrective actions.
- Liquidity: As of December 31, 2010, the company had approximately $12.6 million in cash and short-term investments. It maintains a credit facility with Silicon Valley Bank with approximately $8.0 million in availability. Management believes current resources are sufficient for the next 12 months.
- Unusual Items: The 2009 results were significantly impacted by non-recurring charges (goodwill impairment and DOJ settlement reserve) that did not recur in 2010.
Investor Verification Checklist
- FDA PMA Status: Verify the current status of the ABLATE PMA application and the company's response to the March 2011 FDA deficiency letter.
- Manufacturing Compliance: Confirm the FDA's acceptance of the company's corrective actions regarding the February 2011 Form 483 inspection findings.
- Reimbursement Trends: Monitor third-party payer policies regarding reimbursement for sole-therapy minimally invasive AF ablation, as some payors have recently declined coverage.
- Debt Covenants: Review the company's compliance with financial covenants under its amended credit facility, specifically the minimum EBITDA and adjusted quick ratio requirements.
- Product Adoption: Assess the commercial uptake of the AtriClip system and the new cryoablation devices as drivers for future revenue growth.